Thank you for downloading this publication. Please let us know why you chose this publication:
Why are you interested in this publication?
What organisation do you represent?
You will only need to complete this form once per browser/device
How do you prefer to read or receive publications?

We may contact you for feedback on the publication you have downloaded. If you do not want to be contacted, please leave the email field blank. Your information will never be shared with any third party.

Donate Visit Malaria Consortium U.S.
  • Visit Malaria Consortium U.S.
  • What we do
    • Diseases
    • Policy development and advocacy
    • Research
    • Learning
  • Our expertise
  • Where We Work
    • Africa
    • Burkina Faso
    • Chad
    • Ethiopia
    • Mozambique
    • Nigeria
    • South Sudan
    • Uganda
    • Asia
    • Cambodia
    • Myanmar
    • Thailand
  • Projects
    • Project database
    • Featured projects
    • Past projects
  • Publications
  • Media centre
    • Newsletters
    • News
    • Blog
    • Videos
    • Webinars
    • Press and media
    • Photo stories
    • Voices of experience
  • About us
    • Who we are
    • Governance
    • Aid transparency
    • Dr Sylvia Meek
    • Annual reviews
    • Policies and procedures
    • Careers
    • Tenders
    • Contact us
    • Malaria Consortium U.S.
  • Support us
  • Home
  • »
  • Resources
  • »
  • Publications
  • »
  • Development of weight and age-based dosing of daily primaquine for radical cure of vivax malaria

Share this page

Resources

Latest

Publications

Publication Date:
09/09/2021

Type:
Journal article
Publication

Development of weight and age-based dosing of daily primaquine for radical cure of vivax malaria
Author(s): Walter Robert Taylor, Richard M. Hoglund, Pimnara Peerawaranun, Thuy Nhien Nguyen, Tran Tinh Hien, Arnaud Tarantola, Lorenz von Seidlein, Rupam Tripura, Thomas J. Peto, Arjen M. Dondorp, Jordi Landier, Francois H. Nosten, Frank Smithuis, Koukeo Phommasone, Mayfong Mayxay, Soy Ty Kheang, Chy Say, Kak Neeraj, Leang Rithea, Lek Dysoley, Sim Kheng, Sinoun Muth, Arantxa Roca Feltrer, Mark Debackere, Rick M. Fairhurst, Ngak Song, Philippe Buchy, Didier Menard, Nicholas J. White, Joel Tarning, Mavuto Mukaka

Publication Date:
09/09/2021
Type:
Journal article

Background

In many endemic areas, Plasmodium vivax (P. vivax) malaria is predominantly a disease of young adults and children. International recommendations for radical cure recommend fixed target doses of 0.25 or 0.5 mg/kg/day of primaquine for 14 days in glucose-6-phosphate dehydrogenase normal patients of all ages. However, for many anti-malarial drugs, including primaquine, there is evidence that children have lower exposures than adults for the same weight-adjusted dose. The aim of the study was to develop 14-day weight-based and age-based primaquine regimens against high-frequency relapsing tropical P. vivax.

Methods

The recommended adult target dose of 0.5 mg/kg/day (30 mg in a 60 kg patient) is highly efcacious against tropical P. vivax and was assumed to produce optimal drug exposure. Primaquine doses were calculated using allometric scaling to derive a weight-based primaquine regimen over a weight range from 5 to 100 kg. Growth curves were constructed from an anthropometric database of 53,467 individuals from the Greater Mekong Subregion (GMS) to defne weight-for-age relationships. The median age associated with each weight was used to derive an age-based dosing regimen from the weight-based regimen.

Results

The proposed weight-based regimen has five dosing bands: (i) 5–7 kg, 5 mg, resulting in 0.71–1.0 mg/kg/day; (ii) 8–16 kg, 7.5 mg, 0.47–0.94 mg/kg/day; (iii) 17–40 kg, 15 mg, 0.38–0.88 mg/kg/day; (iv) 41–80 kg, 30 mg, 0.37–0.73 mg/kg/day; and (v) 81–100 kg, 45 mg, 0.45–0.56 mg/kg/day. The corresponding age-based regimen had four dosing bands: 6–11 months, 5 mg, 0.43–1.0 mg/kg/day; (ii) 1–5 years, 7.5 mg, 0.35–1.25 mg/kg/day; (iii) 6–14 years, 15 mg, 0.30–1.36 mg/kg/day; and (iv)≥15 years, 30 mg, 0.35–1.07 mg/kg/day.

Conclusion

The proposed weight-based regimen showed less variability around the primaquine dose within each dosing band compared to the age-based regimen and is preferred. Increased dose accuracy could be achieved by additional dosing bands for both regimens. The age-based regimen might not be applicable to regions outside the GMS, which must be based on local anthropometric data. Pharmacokinetic data in small children are needed urgently to inform the proposed regimens.

Published in Malaria Journal 

Click here to download

Country: Cambodia | Myanmar

Keywords: Research | Child and maternal health | Malaria | Treatment | SDG3

 

 

« Back to Publications

Sign up for our publications newsletter here:

Sign up for our newsletters here:

  • Visit Malaria Consortium U.S.
  • What we do
    • Diseases
    • Policy development and advocacy
    • Research
    • Learning
  • Our expertise
  • Where We Work
    • Africa
    • Burkina Faso
    • Chad
    • Ethiopia
    • Mozambique
    • Nigeria
    • South Sudan
    • Uganda
    • Asia
    • Cambodia
    • Myanmar
    • Thailand
  • Projects
    • Project database
    • Featured projects
    • Past projects
  • Publications
  • Media centre
    • Newsletters
    • News
    • Blog
    • Videos
    • Webinars
    • Press and media
    • Photo stories
    • Voices of experience
  • About us
    • Who we are
    • Governance
    • Aid transparency
    • Dr Sylvia Meek
    • Annual reviews
    • Policies and procedures
    • Careers
    • Tenders
    • Contact us
    • Malaria Consortium U.S.
  • Support us

Language Options: English | Français

© 2022 Malaria Consortium | Charity No. 1099776 | Company No. 4785712 | Privacy notice | Modern Slavery Statement | United Nations Global Compact